NEPH · Nephros Inc · Financials
Market Cap
$48.54M
Shares
10.86M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$18.79M
+32.7%
FY2025
Net Income
$1.19M
+1513.5%
FY2025
Gross Margin
61.87%
+0.3pp
FY2025
Operating Margin
6.1%
+6.1pp
FY2025
Diluted EPS
$0.11
+1000%
FY2025
Operating Cash Flow
$1.6M
+425.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $20.72M | $18.79M | $14.16M | $14.24M | $9.98MG | $10.22M | $8.56M | $10.33M | $5.69M | $3.81M | $2.32M | $1.94M | $1.75M | $1.74M | $1.81M | $2.21M | $2.94M | — | |
| $8.03M | $7.16M | $5.44M | $5.83M | $5.24M | $4.58M | $3.65M | $4.25M | $2.48M | $1.52M | $1.03M | $884K | $549K | $898K | $737K | $1.35M | $1.82M | — | |
| $12.7M | $11.63M | $8.72M | $8.41M | $4.73M | $5.63M | $4.91M | $6.08M | $3.2M | $2.29M | $1.29M | $1.06M | $1.2M | $842K | $1.07M | $868K | $1.12M | — | |
| — | 61.87% | 61.59% | 59.03% | 47.43% | 55.13% | 57.39% | 58.87% | 56.32% | 60.17% | 55.78% | 54.53% | 68.59% | 48.39% | 59.21% | 39.21% | 38.19% | — | |
| $1.45M | $1.34M | $906K | $873K | $1.26M | $1.5M | $2.76M | $3.09M | $1.54M | $1M | $1.08M | $826K | $781K | $867K | $632K | $451K | $362K | — | |
| $9.48M | $9M | $7.68M | $8.91M | $7.59M | $7.2M | $6.47M | $6.12M | $4.52M | $3.3M | $2.85M | $3.44M | $2.87M | $3.07M | $3.62M | $2.64M | $2.52M | — | |
| $32M | $32M | $32K | $42K | $42K | $42K | $42K | $42K | — | — | — | — | — | — | — | — | — | — | |
| $124K | $140K | $135K | $214K | $218K | $192K | $192K | $186K | $163K | $218K | $19K | $1000 | $6000 | $9000 | $9000 | $91K | — | — | |
| $11.05M | $10.48M | $8.72M | $10M | $9.07M | $8.89M | $9.19M | $9.24M | $6.22M | $4.52M | $4.16M | $4.48M | $3.87M | $4.16M | $4.4M | $3.18M | $3.01M | — | |
| $1.64M | $1.15M | $6000 | -$1.59M | -$4.34M | -$3.25M | -$4.28M | -$3.16M | -$3.02M | -$2.23M | -$2.87M | -$3.42M | -$2.67M | -$3.32M | -$3.33M | -$2.31M | -$1.89M | — | |
| — | 6.1% | 0.04% | -11.19% | -43.46% | -31.83% | -49.94% | -30.53% | -53.03% | -58.44% | -123.66% | -175.98% | -152.69% | -190.63% | -184.45% | -104.34% | -64.3% | — | |
| $1.77M | $1.29M | $141K | -$1.38M | -$4.12M | -$3.06M | -$4.08M | -$2.97M | -$2.85M | -$2.01M | -$2.85M | -$3.42M | -$2.66M | -$3.31M | -$3.32M | -$2.22M | — | — | |
| — | $1000 | $1000 | $2000 | $20K | $41K | $110K | $195K | $172K | $302K | $172K | $42K | $483K | $351K | $0 | $12K | $15K | — | |
| — | — | — | — | — | — | — | — | $4000 | $4000 | $5000 | — | — | $0 | $2000 | $4000 | $1000 | — | |
| $110K | $60K | $83K | $18K | $58K | $468K | -$251K | -$54K | -$35K | -$74K | $4000 | $37K | $58K | -$33K | $14K | -$2000 | $20K | — | |
| — | $1.21M | $89K | -$1.58M | — | — | -$4.53M | -$3.4M | -$3.42M | -$2.6M | -$3.03M | — | — | — | — | — | — | — | |
| $16K | $12K | $15K | $0 | $0 | $0 | — | -$225K | -$93K | -$1.79M | — | — | — | — | — | — | — | — | |
| $1.74M | $1.19M | $74K | -$1.58M | -$7.11M | -$3.87M | -$4.53M | -$3.18M | -$3.4M | -$809K | -$3.03M | -$3.09M | -$7.37M | $1.32M | -$6.62M | -$7M | $3.88M | -$12.08M | |
| — | 6.35% | 0.52% | -11.06% | -71.24% | -37.85% | -52.87% | -30.76% | -59.82% | -21.24% | -130.69% | -158.85% | -421.68% | 75.98% | -366.52% | -316.08% | 132.06% | — | |
| — | — | — | — | $276K | $240K | — | $241K | $77K | — | — | — | — | — | — | — | — | — | |
| — | — | — | -$1.58M | -$7.38M | -$4.11M | -$4.77M | -$3.42M | — | — | -$3.03M | -$3.16M | -$7.37M | $1.32M | — | — | $3.88M | — | |
| — | — | — | -$1.58M | -$7.4M | -$4.12M | -$4.76M | -$3.43M | -$3.33M | -$799K | -$3.04M | -$3.09M | -$7.37M | $1.32M | -$6.6M | -$6.97M | -$1.99M | — | |
| USD/shares | $0.16 | $0.11 | $0.01 | -$0.15 | -$0.73 | -$0.41 | — | — | — | — | — | — | -$0.31 | $0.08 | — | — | $1.86 | — |
| USD/shares | $0.16 | $0.11 | $0.01 | -$0.15 | -$0.73 | — | — | — | — | — | — | — | -$0.31 | -$0.18 | — | — | $1.86 | — |
| shares | — | 10.61M | 10.53M | 10.39M | 10.3M | 10.02M | 9.08M | 7.54M | 6.85M | 52.94M | 48.58M | 34.78M | 23.82M | 15.62M | 11.22M | 8.64M | 2.09M | — |
| shares | — | 10.97M | 10.6M | 10.39M | 10.3M | 10.02M | 9.08M | 7.54M | 6.85M | 52.94M | 48.58M | 34.78M | 23.82M | 20.76M | 11.22M | 8.64M | 2.09M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.49×
EV/EBIT
—
Peer median 14.69×
P/E (TTM)
27.94×
Peer median 15.24×
Peer medians compare against the 15 similar-size Medical Instruments & Supplies companies (of 46 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Consolidated | $9,975,000 | $10,217,000 | — |
| Pathogen Detection | — | $187,000 | $29,000 |
| Water Filtration | — | $10,217,000 | $8,532,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product | $18,234,000 | $14,035,000 | $14,110,000 | $9,929,000 | $10,065,000 | $8,453,000 |
| Royalty and Other Revenues | $555,000 | $127,000 | $128,000 | $46,000 | $152,000 | $108,000 |
| Service | $520,000 | $78,000 | — | — | — | — |
| Other Revenue | $24,000 | $43,000 | $97,000 | $46,000 | $73,000 | $40,000 |
| License Royalty and Other Revenue | — | — | — | — | $200,000 | $108,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Renal Products | -$641,000 | -$318,000 | -$1,562,000 |
| Water Filtration | -$3,694,000 | -$2,934,000 | -$1,996,000 |
| Consolidated | -$4,335,000 | -$3,252,000 | — |
| Pathogen Detection | — | -$1,083,000 | -$717,000 |
Operating Margin by Segment (%)
| Component | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Consolidated | -43.5% | -31.8% | — |
| Pathogen Detection | — | -579.1% | -2472.4% |
| Water Filtration | — | -28.7% | -23.4% |